Merck KGaA Says Outcomes-Based Pact With NHS England 'Precedent-Setting'

Merck of Germany says outcomes-based payment arrangements like the one agreed with NHS England for its recently approved multiple sclerosis treatment Mavenclad will become the norm over the next decade, as pharma firms and payors adjust their business models amid increasingly expensive drug innovation and constrained public budgets.

"This could be precedent-setting and become the way business is conducted in future, but it won't happen overnight," Merck...